• Log In
  • Sign Up
    • I’m fascinated with longevity medicine in general. If good medicine is the restoration of health, then great medicine is the preservation of health. Stem cell replacement is just one tool that we will likely use to extend our healthy lifespan. Another such technology is senolytics. Senolytics are compounds that remove old and damaged stem cells from your body. Old stem cells not only cease to function well, they can dysfunction, and become a liability. In fact, I see it likely that we will couple heterochronic transplantation with a senolytic therapy. It’ll be like a stem cell oil change: out with the old, in with the new.

      Since founding Forever Labs, I’ve become friends with Dr. Aubrey de Grey of the SENS Foundation. I give Aubrey great credit for outlining a framework for longevity medicine by identifying the most significant age-related dysfunctions of our biology that must be addressed to preserve health. Aubrey did so long before longevity medicine was cool. Read his book, Ending Aging. It will set the table for what we and others in the space are working on.

    • Forever Labs is continuing to expand its operations, and that keeps me very busy. That said, in addition to expanding our banking services, we have been conducting research regarding stem cell expansion and rejuvenation. In short, we are working on ways to make the most of the cells that we cryopreserve. Can we remove the biologically oldest and most damaged cells from those we collect? Can we rejuvenate the cells that we collect as we grow them in the lab for a future therapy? We think the answer is yes. We are working on it.

    • I post my Forever Labs related thoughts on the Forever Labs blog.

      I’m also just getting active on Twitter ( It’s a personal account, so I am not always speaking in my capacity at Forever Labs on it. Such is the nature of communication these days. I do share my paintings there. You don’t need art school to paint!

    • Thanks, MountainMom! It’s difficult to predict the progress of therapeutics, especially for a treatment like heterochronic transplantation, which is currently in the animal-based research phase. The rate of MSC therapeutic development makes me quite optimistic, but I am hesitant to make predictions. The administration is likely to be intravenous, as many of the MSCs introduced by i.v. return to where they originate, and many MSC therapies in development for age-related diseases are administered this way. I will say that I am keen on using my own cells for heterochronic transplantation, and I do predict that I will be able to do so in a safe and efficacious manner. In fact, we hope to facilitate it by partnering in a clinical trial. I’d love to be able to say “In 10 years we will be doing this...”, but that wouldn’t be an honest answer. I do believe that having cells that are 10 years younger will be an asset however, whether for heterochronic transplantation, or treatment for injury or disease.